B of A Securities Maintains Buy on Turnstone Biologics, Lowers Price Target to $10
Turnstone Biologics Analyst Ratings
Piper Sandler Maintains Turnstone Biologics(TSBX.US) With Buy Rating, Cuts Target Price to $3.75
Piper Sandler Remains a Buy on Turnstone Biologics Corp. (TSBX)
Leerink Partners Maintains Turnstone Biologics(TSBX.US) With Hold Rating
Piper Sandler Keeps Their Buy Rating on Turnstone Biologics Corp. (TSBX)
Piper Sandler Sticks to Its Buy Rating for Turnstone Biologics Corp. (TSBX)
Leerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. (TSBX) Receives a Buy From Piper Sandler
Turnstone Biologics Analyst Ratings
No Data